UNSPSC 51141504: Lamotrigine

This classification denotes an anticonvulsant agent with the molecular formula C9H7Cl2N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3H27498KS, chemically known as 1,2,4-triazine-3,5-diamine, 6-(2,3-dichlorophenyl)- but generally known as lamotrigine, which bears US NIH Compound Identifier 3878. European Medicines Agency schedules Lamotrigine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08393MIG.

UNSPSC 51141504 Lamotrigine is a Commodity code nominally covering a specific anticonvulsant pharmaceutical product, but the recent state and local procurement activity tagged under this code does not reflect lamotrigine purchases. The single recent opportunity on record—Seminole County, Florida's IFB60459723LAS—solicits naloxone and safe drug deactivation systems, which fall outside the nominal scope of the code. State and local procurement offices occasionally tag opportunities with codes that do not align with the actual goods being bought, and this appears to be one such mismatch. The code shows no relevant recent activity for the pharmaceutical indicated by its name.

Seminole County posted the naloxone and drug deactivation systems procurement on June 30, 2026, with a response deadline of July 26, 2026 (the summary also references an earlier posting date of July 10, 2023, which may reflect a prior solicitation cycle). The county seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must include all shipping and delivery costs in their bids, submit proposals electronically through the county's e-Procurement Portal, and comply with drug-free workplace certification, E-Verify requirements, and applicable federal compliance standards. The contract includes a two-year initial term with an option for one-year renewal and a three-month probationary period. No explicit set-aside designations for disadvantaged enterprises are specified in the procurement. Business development professionals evaluating this code should treat it as inactive for lamotrigine and flag the coding mismatch with their procurement intelligence sources.